Cathie Wood just scooped up shares in one particular big tech artificial intelligence (AI) stock. For the last couple of years, the stock market has rallied on an unwaveringly positive narrative ...

Leerink Partners lowered 10x Genomics from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $25.00 to $12.00 in a research report on Thursday.

Of course, I'm talking about Ark Invest CEO Cathie Wood-- who almost always seems to exhibit a sense of optimism when it comes to new technologies. I'll reveal which Magnificent Seven stock Wood ...

10x Genomics, Inc. (NASDAQ:TXG – Get Free Report)’s stock price gapped down prior to trading on Thursday following a dissappointing earnings announcement. The stock had previously closed at $ ...

Genomics is the study of the full genetic complement of an organism (the genome). It employs recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyse the ...

Cathie Wood's ARK ETFs have disclosed their daily trades for Monday, February 10th, 2025, with notable transactions across a range of technology and biotech stocks. The largest trade of the day ...

Cathie Wood's comeback could continue through the year ... It features a software stock we’re confident has 10X potential. Undoubtedly, the rise of the incredibly cheap and efficient DeepSeek ...

"This is a win for the research community," the company's the CEO says. The lawsuit against the company was filed in August 2022. Seattle-based Parse Biosciences secured another major legal ...